← Back to Search

Tyrosine Kinase Inhibitor

Apatinib with Nivolumab for Cancer

Phase 1
Waitlist Available
Research Sponsored by Elevar Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 5 years
Awards & highlights

Study Summary

This is an open-labeled, single-center, Phase I study to evaluate the safety, tolerability, and efficacy of apatinib with nivolumab treatment in participants with unresectable or metastatic cancer. Total study duration will be approximately 50 months: 12 months of recruitment plus 6 months of treatment and subsequent survival follow up.

Eligible Conditions
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Best Overall Response Rate (BOR)
Disease Control Rate (DCR)
Duration of Disease Control (DDC)
+4 more
Secondary outcome measures
Event Free Survival (EFS)
Overall Survival (OS)
Progression Free Survival (PFS)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Apatinib with NivolumabExperimental Treatment2 Interventions
Participants will receive an oral dose of apatinib once per day with a fixed dose of nivolumab given intravenously every 2 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Apatinib
2018
Completed Phase 4
~1620
Nivolumab
2014
Completed Phase 3
~4750

Find a Location

Who is running the clinical trial?

Elevar TherapeuticsLead Sponsor
8 Previous Clinical Trials
717 Total Patients Enrolled
Steven Norton, PhDStudy DirectorElevar Therapeutics
2 Previous Clinical Trials
109 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer
2017. "A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03396211.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top